Fight against antibiotic crisis stymied by lack of R&D spend
A “concerning shortfall” in investment in costly late stage research and development (R&D) to battle antimicrobial resistance (AMR) means that future global health needs are unlikely to be met, according to a report by private sector coalition the AMR Industry Alliance.
The Alliance says this is despite its members stumping up US $1.6 billion for the purpose in 2018 and steps including continued investment in early R&D for products to tackle AMR such as antibiotics, vaccines and disease diagnostics.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.